Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
Almost from the day in 1995 that GlaxoSmithKline introduced Flonase, it was a runaway hit. The nasal spray alleviated seasonal allergy symptoms without causing drowsiness, and Americans (50 million of whom have allergies) clamored for a prescription. Flonase did $600 million in sales by 2000, and in 2005 raked in $1.3 billion. But Flonase's patent expired that year, opening the door to generic competitors. So when GSK returned to the market with an over-the-counter formulation last year, it needed an aggressive marketing plan.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in